More Evidence Empagliflozin Protects the Kidneys More Evidence Empagliflozin Protects the Kidneys

New data from the EMPA-REG-OUTCOME study provide more evidence of the renoprotective effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with type 2 diabetes and cardiovascular disease.Reuters Health Information

Source: Medscape Medical News Headlines - July 10, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news